No Data
Shanghai Pharmaceuticals Gets Clinical Trial Approval for Varicose Vein Treatment
Shanghai Pharmaceuticals Gets US FDA Orphan Drug Designation for ALS Drug
SH PHARMA: SRD4610 has obtained orphan drug designation from the USA FDA.
On December 10, 2023, SH PHARMA (601607.SH) announced that its wholly-owned subsidiary, Shanghai Shangyao Ruir Pharmaceutical Co., Ltd., has independently developed SRD4610 for the treatment of amyotrophic lateral sclerosis (ALS) and received orphan drug designation from the USA Food and Drug Administration (referred to as "USA FDA"). SRD4610 is a compound Traditional Chinese Medicine Innovative Drug, and the project has completed a Phase II clinical trial for ALS in China.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).
On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
